Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company's platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal's immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company's advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:NVET
- CUSIP: N/A
- Web: www.nexvet.com/
- 52 Week Range: $2.75 - $6.72
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.11
- P/E Growth: 0.00
- Return on Equity: -102.72%
- Return on Assets: -89.82%
- Current Ratio: 5.34%
- Quick Ratio: 5.34%
Frequently Asked Questions for Nexvet Biopharma plc (NASDAQ:NVET)
What is Nexvet Biopharma plc's stock symbol?
Nexvet Biopharma plc trades on the NASDAQ under the ticker symbol "NVET."
How were Nexvet Biopharma plc's earnings last quarter?
Nexvet Biopharma plc (NASDAQ:NVET) issued its quarterly earnings data on Thursday, May, 11th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02. View Nexvet Biopharma plc's Earnings History.
Where is Nexvet Biopharma plc's stock going? Where will Nexvet Biopharma plc's stock price be in 2017?
1 brokers have issued 12 month price targets for Nexvet Biopharma plc's stock. Their forecasts range from $6.72 to $6.72. On average, they expect Nexvet Biopharma plc's share price to reach $6.72 in the next twelve months. View Analyst Ratings for Nexvet Biopharma plc.
Who are some of Nexvet Biopharma plc's key competitors?
Some companies that are related to Nexvet Biopharma plc include Amgen (AMGN), Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Kite Pharma (KITE), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), AveXis (AVXS), Sarepta Therapeutics (SRPT) and GW Pharmaceuticals PLC (GWPH).
When did Nexvet Biopharma plc IPO?
(NVET) raised $58 million in an IPO on Thursday, February 5th 2015. The company issued 4,000,000 shares at $13.00-$16.00 per share. BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Piper Jaffray and JMP Securities were co-managers.
Who owns Nexvet Biopharma plc stock?
Nexvet Biopharma plc's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Farallon Capital Management LLC (0.00%), Broadfin Capital LLC (0.00%), Kassirer Asset Management Corp (1.01%), GABELLI & Co INVESTMENT ADVISERS INC. (0.60%), GLG Partners LP (0.00%) and S. Muoio & CO. LLC (0.48%). Company insiders that own Nexvet Biopharma plc stock include Ashraf Hanna, Cormac G Kilty, David Gearing and Farallon Capital Management Ll. View Institutional Ownership Trends for Nexvet Biopharma plc.
Who bought Nexvet Biopharma plc stock? Who is buying Nexvet Biopharma plc stock?
Nexvet Biopharma plc's stock was bought by a variety of institutional investors in the last quarter, including Kassirer Asset Management Corp, GABELLI & Co INVESTMENT ADVISERS INC., GLG Partners LP, S. Muoio & CO. LLC, Harvest Management LLC and Glazer Capital LLC. Company insiders that have bought Nexvet Biopharma plc stock in the last two years include Ashraf Hanna, Cormac G Kilty, David Gearing and Farallon Capital Management Ll. View Insider Buying and Selling for Nexvet Biopharma plc.
How do I buy Nexvet Biopharma plc stock?
Shares of Nexvet Biopharma plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nexvet Biopharma plc's stock price today?
MarketBeat Community Rating for Nexvet Biopharma plc (NASDAQ NVET)MarketBeat's community ratings are surveys of what our community members think about Nexvet Biopharma plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Nexvet Biopharma plc stock can currently be purchased for approximately $6.72.
Consensus Ratings for Nexvet Biopharma plc (NASDAQ:NVET) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||$6.72 (0.00% downside)|
Analysts' Ratings History for Nexvet Biopharma plc (NASDAQ:NVET)
(Data available from 9/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|4/24/2017||Credit Suisse Group||Downgrade||Outperform -> Neutral||$8.00 -> $6.72||Low|
|11/24/2015||Cowen and Company||Reiterated Rating||Buy||$13.00||N/A|
|11/24/2015||Piper Jaffray Companies||Reiterated Rating||Overweight||$17.00 -> $13.00||N/A|
Earnings History for Nexvet Biopharma plc (NASDAQ:NVET)Earnings History by Quarter for Nexvet Biopharma plc (NASDAQ NVET)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Nexvet Biopharma plc (NASDAQ:NVET)
Current Year EPS Consensus Estimate: $-1.75 EPS
Next Year EPS Consensus Estimate: $-1.10 EPS
Dividend History for Nexvet Biopharma plc (NASDAQ:NVET)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Nexvet Biopharma plc (NASDAQ:NVET)
Insider Ownership Percentage: 37.00%Insider Trades by Quarter for Nexvet Biopharma plc (NASDAQ:NVET)
Institutional Ownership Percentage: 48.38%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/4/2016||David Gearing||Insider||Buy||11,113||$3.33||$37,006.29|| |
|3/2/2016||Ashraf Hanna||Director||Buy||1,500||$3.20||$4,800.00|| |
|2/26/2016||Farallon Capital Management Ll||Insider||Buy||435,000||$3.19||$1,387,650.00|| |
|2/24/2016||Cormac G Kilty||Director||Buy||3,000||$3.17||$9,510.00|| |
|9/10/2015||Farallon Capital Management Ll||Insider||Buy||11,100||$6.46||$71,706.00|| |
|9/9/2015||Cormac G Kilty||Director||Buy||10,000||$4.79||$47,900.00|| |
|2/10/2015||One Funds Management Ltd Atf A||Major Shareholder||Buy||100,000||$10.00||$1,000,000.00|| |
Headline Trends for Nexvet Biopharma plc (NASDAQ:NVET)
Latest Headlines for Nexvet Biopharma plc (NASDAQ:NVET)
|Nexvet Biopharma plc (NVET) Set to Announce Quarterly Earnings on Thursday|
www.americanbankingnews.com - August 24 at 1:15 AM
|Nexvet Biopharma plc ("Nexvet") Rule 17(d) Announcement|
finance.yahoo.com - July 29 at 5:43 AM
|Nexvet Biopharma plc ("Nexvet") Rule 17(c) Announcement|
finance.yahoo.com - July 11 at 6:05 AM
|Nexvet Biopharma plc ("Nexvet") Supplement Announcement|
finance.yahoo.com - July 4 at 2:25 AM
|SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Nexvet Biopharma plc and Encourages Investors to Contact the Firm for Additional Information|
finance.yahoo.com - June 22 at 8:05 AM
|WeissLaw LLP Files Class Action Lawsuit Against Nexvet Biopharma PLC|
finance.yahoo.com - June 19 at 6:01 PM
|Nexvet Biopharma plc ("Nexvet") Rule 15 Announcement|
finance.yahoo.com - June 16 at 8:21 AM
|Nexvet Biopharma plc ("Nexvet") Rule 17(b) Announcement|
finance.yahoo.com - June 7 at 12:42 AM
|Nexvet Biopharma plc ("Nexvet") Rule 17 Announcement|
finance.yahoo.com - June 2 at 8:51 PM
|SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Filing of a Complaint Concerning Whether the Sale of Nexvet Biopharma Public Limited Company to Zoetis Inc. for $6.72 Per Share is Fair to Shareholders|
finance.yahoo.com - June 2 at 8:51 PM
|Nexvet Biopharma plc (NVET) Upgraded to Hold at Zacks Investment Research|
www.americanbankingnews.com - May 18 at 9:02 PM
|Nexvet Biopharma plc (NVET) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS|
www.americanbankingnews.com - May 12 at 2:02 PM
|Nexvet Biopharma plc ("Nexvet") Rule 2.10 Announcement|
finance.yahoo.com - May 12 at 12:26 AM
|Nexvet Reports Financial Results for Third Quarter of Fiscal Year 2017|
finance.yahoo.com - May 11 at 9:17 AM
|Nexvet Biopharma plc (NVET) Earns Coverage Optimism Score of -0.12|
www.americanbankingnews.com - May 4 at 12:08 PM
| Brokerages Expect Nexvet Biopharma plc (NVET) Will Post Earnings of -$0.47 Per Share|
www.americanbankingnews.com - May 3 at 12:04 AM
|Nexvet Biopharma plc (NVET) Getting Somewhat Negative Media Coverage, Study Finds|
www.americanbankingnews.com - May 1 at 4:42 PM
|Nexvet Biopharma plc (NVET) Earns Daily Media Sentiment Rating of 0.09|
www.americanbankingnews.com - April 28 at 8:22 PM
|Nexvet Biopharma plc (NVET) Receives Daily Media Sentiment Rating of 0.40|
www.americanbankingnews.com - April 25 at 11:48 AM
|Nexvet Biopharma plc (NVET) Stock Rating Lowered by Credit Suisse Group AG|
www.americanbankingnews.com - April 24 at 9:10 PM
|Nexvet Biopharma plc (NVET) Given Media Impact Rating of -0.08|
www.americanbankingnews.com - April 19 at 12:11 PM
|Zoetis To Acquire Nexvet Biopharma For Animal Pain Management|
seekingalpha.com - April 17 at 6:08 PM
|Zoetis (ZTS) Inks Agreement to Acquire Nexvet Biopharma|
finance.yahoo.com - April 17 at 6:08 PM
|Nexvet Biopharma plc (NVET) Earns Daily Media Impact Score of 0.28|
www.americanbankingnews.com - April 15 at 2:55 PM
|Zoetis to Acquire Nexvet for US$6.72 in Cash Per Share|
www.businesswire.com - April 13 at 6:41 PM
| Analysts Anticipate Nexvet Biopharma plc (NVET) Will Announce Earnings of -$0.47 Per Share|
www.americanbankingnews.com - April 11 at 6:06 PM
|Nexvet Biopharma plc (NVET) Sees Large Increase in Short Interest|
www.americanbankingnews.com - April 11 at 9:55 AM
|Nexvet Biopharma plc (NVET) Rating Increased to Hold at Zacks Investment Research|
www.americanbankingnews.com - April 11 at 9:28 AM
|Nexvet Biopharma plc (NVET) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - April 5 at 1:46 PM
|Nexvet Biopharma plc (NVET) Cut to "Sell" at Zacks Investment Research|
www.americanbankingnews.com - March 29 at 7:05 AM
|Nexvet Biopharma plc (NVET) Downgraded to Sell at Zacks Investment Research|
www.americanbankingnews.com - March 23 at 11:58 PM
|NEXVET BIOPHARMA PLC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits|
biz.yahoo.com - March 13 at 10:00 AM
|Nexvet to Present at the Cowen and Company 37th Annual Health Care Conference|
finance.yahoo.com - March 2 at 8:58 AM
|Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2017|
us.rd.yahoo.com - February 10 at 7:54 PM
|Q2 2017 Nexvet Biopharma plc Earnings Release - Time Not Supplied|
biz.yahoo.com - February 10 at 7:54 PM
|Nexvet Announces Initiation of Pivotal Efficacy Study of Frunevetmab in Cats|
finance.yahoo.com - December 12 at 10:00 AM
|NEXVET BIOPHARMA PLC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission|
biz.yahoo.com - November 18 at 9:45 AM
|Nexvet to Present at the 25th Annual Credit Suisse Healthcare Conference|
finance.yahoo.com - October 19 at 11:35 AM
|NEXVET BIOPHARMA PLC Financials|
finance.yahoo.com - September 7 at 6:39 PM
|NEXVET BIOPHARMA PLC Files SEC form 10-K, Annual Report|
biz.yahoo.com - September 2 at 11:21 AM
|Q4 2016 Nexvet Biopharma plc Earnings Release - Time Not Supplied|
biz.yahoo.com - September 2 at 11:21 AM
|NEXVET BIOPHARMA PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi|
biz.yahoo.com - September 2 at 11:21 AM
|Nexvet Announces Publication of Two Peer-Reviewed Journal Articles Profiling Frunevetmab (NV-02) and Presentation at the Veterinary Pain Short Course Conference|
finance.yahoo.com - July 20 at 5:30 AM
Nexvet Biopharma plc (NVET) Chart for Friday, September, 22, 2017